Traditional go-to-market approaches are failing to bring gene therapies that offer the promise of a 'cure' to patients.
In this webinar we will discuss the need and introduce frameworks for integrated, cross-functional approaches imperative to drive patient access and commercial success. We will also show examples of how these frameworks can be applied to address the commercialisation challenges of these disruptive therapies.
Life science companies face a rapidly evolving landscape, leading to strategic opportunities as well as challenges including the threat of disruption. Huron's life science practice is part of Huron’s continuum of healthcare offerings supporting the development and commercialisation of pharmaceutical products and services.
At Huron, we work with life science companies who typically focus on:
- Developing winning strategies and new innovative business models that go beyond individual assets and capabilities
- Building value and making a difference to all stakeholders throughout the healthcare continuum
- Achieving affordable access to therapies while managing uncertainty around underlying data
- Harnessing the power of new technologies and approaches such as digital solutions, use of real-world evidence and analytics, and companion diagnostics